reports
An unfavourable environment weighs on ONCOMED PHARMS.INCO., which sees...
The independent financial analyst theScreener just requalified the general evaluation of ONCOMED PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date April 16, 2019, the closing price was...
OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results
OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results REDWOOD CITY, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced fourth quarter and full year 2018 financial results. Recent Corporate News On December 5, 2018, OncoMed and Mereo BioPharma Group plc (Mereo), a clinical-stage UK-based biopharmaceutical company, agreed to enter into a proposed combination of the two companies, subject to approval by OncoMed ...
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals To be effected by an all-stock transaction plus issuance of Contingent Value Rights (“CVRs”); completion expected H1 2019 Deal broadens asset and shareholder base and extends Enlarged Group cash runway Enlarged Group expects to launch new NASDAQ-Listed ADR programme Conference call and webcast today with Dr Denise Scots-Knight and Dr John Lewicki, 8:30 a.m. ET / 1:30 p.m. GMT THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 ("MAR"). UPON PUBLICATION OF THIS ...
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage Solid Tumors REDWOOD CITY, Calif. and WASHINGTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced initial results from the Phase 1a dose escalation portion of a Phase 1a/b trial of etigilimab, the company’s anti-TIGIT antibody. TIGIT ...
OncoMed Announces Third Quarter 2018 Financial Results and Operational...
OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights -Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer; -Prepares for presentation of etigilimab data at Society for Immunotherapy of Cancer (SITC) Annual Meeting REDWOOD CITY, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced third quarter 2018 finan...
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Pacli...
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced interim results from its ongoing Phase 1b trial i...
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Pacli...
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab REDWOOD CITY, Calif., Oct. 20, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced interim results from its ongoing Phase 1b trial i...
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase...
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that interim results of its ongoing Phase 1b study of navicixizumab in combination with paclitaxel in patients with platinum-resistant ovarian cancer will be presented in a poster presentation on October 20, 2018 at the European Soci...
OncoMed to Present at the Cantor Global Healthcare Conference
OncoMed to Present at the Cantor Global Healthcare Conference REDWOOD CITY, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed, will present a corporate update at the 2018 Cantor Global Healthcare Conference in New York, NY on Monday, October 1, 2018 at 5:15 pm Eastern Time. To access the live webcast and subsequent archived recording of this presenta...
OncoMed Announces Publication of Phase 1a Data of Navicixizumab
OncoMed Announces Publication of Phase 1a Data of Navicixizumab Objective Responses Observed in Heavily-pretreated Ovarian Cancer Patients Treated with Navicixzumab Monotherapy REDWOOD CITY, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the results of its Phase 1a study with single-agent navicixizumab in patients with refractory solid tumors were published in . The results showed that 19 of the 66 patients with va...
OncoMed Provides Update on Navicixizumab Partnership
OncoMed Provides Update on Navicixizumab Partnership REDWOOD CITY, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that Celgene has notified OncoMed that due to strategic product portfolio considerations Celgene has decided not to exercise its option to license OncoMed’s bispecific antibody navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83). Celgene continues to retain its options to license OncoMed’s etigilimab (anti-T...
OncoMed to Present at Two Upcoming Investor Conferences in September
OncoMed to Present at Two Upcoming Investor Conferences in September REDWOOD CITY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed, will provide a corporate update at two upcoming investor conferences. Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on September 5, 2018 at 9:40 am Eastern Time20th Annual Rodman & Renshaw Global Inves...
OncoMed Announces Second Quarter 2018 Financial Results and Operationa...
OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights -Company prioritizes its navicixizumab resources in platinum-resistant ovarian cancer; prepares to share data in Q4 of 2018- -Cash runway extended by an additional quarter to YE 2019- REDWOOD CITY, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced second quarter 2018 financial results and provided a corporate update. As of June 30, 2018, cash...
- GlobalData Department
OncoMed Pharmaceuticals Inc (OMED) - Medical Equipment - Deals and All...
Summary OncoMed Pharmaceuticals Inc. (OncoMed) is a clinical-stage biopharmaceutical company that discovers and develops new anti-cancer therapies. The company developed pipeline candidates that obstruct the evasive mechanisms of tumor cells, increasing the visibility of such tumor cells, which leads to increasing attacks by the immune system and enhancing immune cell activity. Its clinical stage pipeline product candidates include navicixizumab, rosmantuzumab, Gitrl-FC Trimer, vantictumab, ant...
OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical...
OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial Expanded Phase of Trial will Assess anti-TIGIT in Combination with anti-PD1 REDWOOD CITY, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the first patient has been dosed in the company’s Phase 1b portion of the Phase 1a/1b clinical trial of anti-TIGIT (OMP-313M32) in combination with anti-PD1 (nivolumab). TIGIT (T-cell immunoreceptor with I...
Newman Ferrara LLP Announces Corporate Governance Investigation of Onc...
NEW YORK--(BUSINESS WIRE)-- Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of OncoMed Pharmaceuticals Inc. (“OncoMed” or the “Company”) (NASDAQ:OMED) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). OncoMed, headquartered in Redwood City, CA, is a clinical-stage, biopharmaceutical company. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly di...
Newman Ferrara LLP Announces Corporate Governance Investigation of Onc...
NEW YORK--(BUSINESS WIRE)-- Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of OncoMed Pharmaceuticals Inc. (“OncoMed” or the “Company”) (NASDAQ:OMED) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). OncoMed, headquartered in Redwood City, CA, is a clinical-stage, biopharmaceutical company. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly di...
- GlobalData Healthcare Department
OncoMed Pharmaceuticals Inc (OMED) - Financial Analysis Review
Summary OncoMed Pharmaceuticals Inc (OMED) - Financial Analysis Review Summary OncoMed Pharmaceuticals Inc (OncoMed) focuses on the discovery and development of monoclonal antibody therapeutics which targets cancer stem cells. The company's clinical stage pipeline product candidate includes demcizumab, vantictumab, tarextumab, ipafricept, anti-RSPO3, brontictuzumab and anti-DDL4/VEGF. OncoMed’s expertise spans oncology research, drug discovery, clinical development, regulatory affairs, tran...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.